Donnerstag, 23. Februar 2017


  • Pressemitteilung BoxID 542946

Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV

(lifePR) (OXFORD, United Kingdom and MARLBOROUGH, Mass, ) Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patient has been enrolled in the REACT study. The REACT study, which focuses on stem cell transplant patients, is the second of two pivotal clinical trials designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV test.

"We are happy to announce that the enrollment process is underway, on schedule, for our REACT study," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We remain excited about the potential clinical and economic value of our T-SPOT.CMV test."

About the T-SPOT.CMV test

Our T-SPOT.CMV test measures the strength of T cell responses to Cytomegalovirus (CMV) to assess susceptibility to CMV infection. CMV disease is a common and serious complication in both solid organ and stem cell transplantation. Our T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform.

Oxford Immunotec Inc.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company's second product and the first in a series of products intended for the transplantation market. The Company has six additional active development programs, each of which leverages our T cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Diese Pressemitteilungen könnten Sie auch interessieren

Neue Langzeitstudie zu Brust-OPs zeigt: Die verträglichsten Silikonimplantate kommen aus Deutschland

, Gesundheit & Medizin, POLYTECH Health & Aesthetics GmbH

Die Brustvergrößerung mit Silikonimplantaten ist nach wie vor eine der beliebtesten Schönheitsoperatione­n in Deutschland[1]. Schönheits-OPs...

Studie: Viren unterstützen Fotosynthese bei Bakterien - Vorteil in der Evolution?

, Gesundheit & Medizin, TU Technische Universität Kaiserslautern

Viren verbreiten sich, indem sie eine Wirtszelle befallen und sich in ihr vermehren. Betroffen hiervon sind nicht nur Menschen und Tiere, sondern...

STUDIE Schönheitsoperationen in Deutschland: In Berlin kostet das Lifting 5.944 Euro, in Stuttgart nur 4.660 Euro

, Gesundheit & Medizin, Junomedical GmbH

Eine bundesweite Studie des Portals Junomedical.com zeigt große Preisunterschiede innerhalb Deutschlands. Wer sich für ein faltenfreies Gesicht...

Disclaimer